Rutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes ...
Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has debuted a framework that is designed to help companies move away from the use of non ...
The guidance clarifies what sponsors should consider when putting together an application for the validation of a NAM ...
The FDA has released draft guidance that aims to clear up how drug developers can use alternative testing – but that doesn’t ...
Researchers at the University of Plymouth are leading an innovative initiative to advance the study of meningiomas in NF2-related schwannomatosis (NF2-SWN). Meningiomas, often linked to the loss of ...
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--MED Institute, a leader in pre-clinical and clinical medical product development services, is proud to announce a strategic collaboration with Sus Clinicals, a ...
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc ...
Plasma phosphorylated (p)-tau217 testing can help identify preclinical Alzheimer's disease (AD), which could aid clinical trial recruitment. Recruiting preclinical AD participants for clinical ...
The FDA has released a draft guidance outlining how drug developers can validate new approach methodologies (NAMs) as ...
Kymera Therapeutics has announced that Sanofi will advance their next-generation oral IRAK4 degrader, KT-485, into clinical testing, while opting not to pursue KT-474. Preclinical studies indicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results